Mylan
Mylan CEO to appear before US congress over EpiPen scandal
September 15, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Hilary Clinton, Mylan, epipen
Following the controversy of Mylan’s price increases to its EpiPen (epinephrine) auto-injector, the company’s CEO Heather Bresch is due to …
Antitrust investigation launched into Mylan and the EpiPen scandal
September 7, 2016Research and Development, Sales and Marketing Mylan, US, antitrust, epipen, investigation, lawmakers, scandal
The New York attorney general has commenced an investigation into Mylan Pharmaceuticals, after an initial review indicated that the company …
EMA accepts regulatory submission for proposed Herceptin biosimilar
August 26, 2016Medical Communications Biocon, EMA, Herceptin, Mylan, biosimilar, regulatory, submission, trastuzumab
Mylan and Biocon have announced that the European Medicines Agency (EMA) has accepted for review its marketing authorisation application for …
Mylan announces immediate plans to cut price of EpiPen
August 25, 2016Medical Communications, Research and Development Mylan, clinton, epipen, increase
Subject to intense pressure over the last few days, Mylan has made an attempt to avoid becoming “another Valeant” by …
Teva loses patent protection on lucrative MS treatment
August 25, 2016Manufacturing and Production, Research and Development, Sales and Marketing Copaxone, Mylan, Teva, multiple sclerosis
Teva’s stock plunged 3% after a US agency ruled that two of its patents related to multiple sclerosis drug Copaxone …
Mylan latest target of US anger on drug pricing with EpiPen price increase
August 24, 2016Research and Development, Sales and Marketing Mylan, US, congress, controversy, epipen, price gouging, price increase
The US congress is again subjecting the pharmaceutical industry to heavy scrutiny over drug pricing policies with Mylan its latest …
Mylan’s breast cancer biosimilar matches Roche’s Herceptin in Phase III trial
June 6, 2016Research and Development ASCO, Biocon, Herceptin, Mylan, Roche, biosimilar, breast cancer, trastuzumab
Mylan (NASDAQ: MYL) and Biocon (NSE: BIOCON) have presented data the 2016 American Society of Clinical Oncology (ASCO) annual meeting …
Mylan to buy Renaissance’s dermatology business for up to $1 billion
May 16, 2016Research and Development, Sales and Marketing Mylan, generics, merger and acquisition
Generics maker Mylan (Nasdaq: MYL) has agreed to buy skincare products from Renaissance Acquisition Holdings for up to $1 billion. …
New CFO at Mylan
May 3, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Mylan, cfo, kenneth parks
Mylan has announced the appointment of Kenneth S. Parks as its new chief financial officer, effective June 6 2016. Parks …
Mylan Q1 revenue up 17%, maintains FY view
May 3, 2016Manufacturing and Production, Sales and Marketing Financial, Mylan, Q1, results, revenue, sales
Pharma firm Mylan NV (Nasdaq: MYL) on Tuesday reported a 17% rise in first-quarter revenue and said it maintains its …
Mylan launches new dosages of generic of Novartis hypertension drug in US
April 11, 2016Manufacturing and Production Mylan, Novartis, generic, high blood pressure, hypertension
Mylan (TASE: MYL) has announced the US launch of new dosages of its generic version of Novartis’s hypertension drug, Lopressor …
Mylan launches generic of Valeant’s Ultram in the US
March 29, 2016Manufacturing and Production, Sales and Marketing FDA, Mylan, Valeant, abbreviate new drug application, generic, pain, tramadol, ultram
Mylan (NASDAQ, TASE: MYL) has announced the launch of its generic version of Valeant’s Ultram tablets in the US. The …
Mylan announces Momenta collaboration to develop six biosimilars
January 8, 2016Manufacturing and Production, Sales and Marketing Heather Bresch, Momenta, Mylan, biosimilars
Mylan has entered an exclusive global collaboration agreement with Momenta Pharmaceuticals, to develop, manufacture and commercialise six of Momenta’s biosimilar …
Mylan receives court summons from US Department of Justice
December 7, 2015Sales and Marketing Drug pricing, Justice department, Mylan, US Department of Justice, generics, investigation, subpoena
The US Department of Justice has contacted Mylan to make enquiries about the company’s pricing structure for antibiotic, doxycycline. Mylan …
Mylan launches digital adherence programme for heart patients
November 27, 2015Medical Communications Canada, Mavik, Mylan, pharmacies, trandolapril
Mylan has launched an innovative digital medication adherence and engagement program for patients with high blood pressure. The digital programme, called …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
